Targeting SRC with inhibitors such as dasatinib and NXP900 has demonstrated potent antitumor effects, and when combined with standard chemotherapy, these agents amplify cancer cell death and suppress tumor progression [54]. The gene discussed is SRC; the disease is neoplasm.